T1	Participants 41 173	study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
T2	Participants 186 237	Targeted agents presently available for mutant KRAS
T3	Participants 238 305	metastatic colorectal cancer (mCRC) are bevacizumab and aflibercept
T4	Participants 324 358	efficacy and safety of conatumumab
T5	Participants 429 438	ganitumab
T6	Participants 645 848	Patients with mutant KRAS metastatic adenocarcinoma of the colon or rectum refractory to fluoropyrimidine- and oxaliplatin-based chemotherapy were randomized 1 : 1 : 1 to receive intravenous FOLFIRI plus
T7	Participants 1008 1036	155 patients were randomized
T8	Participants 1057 1083	A, B, and C was 6.5 months
T9	Participants 1145 1170	4.6 months, respectively;
T10	Participants 1171 1210	median overall survival was 12.3 months
T11	Participants 1273 1333	12.0 months; and objective response rate was 14%, 8%, and 2%
T12	Participants 1357 1374	â‰¥3 adverse events
T13	Participants 1463 1555	Conatumumab, but not ganitumab, plus FOLFIRI was associated with a trend toward improved PFS
T14	Participants 1557 1598	Both combinations had acceptable toxicity
